STOCK TITAN

[Form 4] Cardio Diagnostics Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Peter Fung, a director of Cardio Diagnostics Holdings, Inc. (CDIO), reported a non-derivative change tied to stock options dated 09/30/2025. The filing shows 1,559 stock options were acquired with an exercise price of $4.01, exercisable immediately and expiring on 09/30/2035. After the transaction, Mr. Fung beneficially owned 4,002 shares of common stock on a direct basis.

Peter Fung, un direttore di Cardio Diagnostics Holdings, Inc. (CDIO), ha riportato una variazione non derivativa legata a stock options datata 09/30/2025. La filing mostra che 1,559 stock options sono state acquisite con un prezzo di esercizio di $4.01, esercitabili immediatamente e con scadenza il 09/30/2035. Dopo la transazione, il signor Fung deteneva direttamente 4,002 azioni ordinarie.

Peter Fung, un director de Cardio Diagnostics Holdings, Inc. (CDIO), informó un cambio no derivado vinculado a opciones sobre acciones con fecha 09/30/2025. El trámite muestra que se adquirieron 1,559 opciones sobre acciones con un precio de ejercicio de $4.01, exercitables de inmediato y con vencimiento el 09/30/2035. Después de la transacción, el Sr. Fung poseía directamente 4,002 acciones ordinarias.

Peter Fung, 이사Cardio Diagnostics Holdings, Inc. (CDIO)의 비파생적 변화가 09/30/2025에 주식매수선택권과 관련해 보고되었습니다. 공시에는 1,559 주식 옵션이 $4.01의 행사 가격으로 즉시 행사 가능하며 2035/09/30에 만료됩니다. 거래 후 펑 씨는 직접 보유한 일반 주식 4,002주를 소유하게 되었습니다.

Peter Fung, directeur de Cardio Diagnostics Holdings, Inc. (CDIO), a déclaré une modification non dérivée liée à des options sur actions datée du 09/30/2025. Le dépôt indique que 1 559 options sur actions ont été acquises avec un prix d’exercice de $4.01, exercables immédiatement et arrivant à échéance le 09/30/2035. Après la transaction, M. Fung détenait directement 4 002 actions ordinaires.

Peter Fung, ein Direktor von Cardio Diagnostics Holdings, Inc. (CDIO), meldete eine nicht derivative Veränderung im Zusammenhang mit Aktienoptionen datiert auf 09/30/2025. Die Einreichung zeigt, dass 1.559 Aktienoptionen mit einem Ausübungspreis von $4.01 erworben wurden, sofort ausübbar und am 09/30/2035 fällig. Nach der Transaktion besaß Herr Fung direkt 4.002 Stammaktien.

Peter Fung، مدير في Cardio Diagnostics Holdings, Inc. (CDIO)، أبلغ عن تغير غير مشتق مرتبط بخيارات الأسهم والمؤرخة في 09/30/2025. يظهر الملف أن 1,559 خياراً لسهم تم شراؤها بسعر تنفيذ قدره $4.01، قابل للتنفيذ على الفور وينتهي في 09/30/2035. بعد الصفقة، امتلك السيد Fung بشكل مباشر 4,002 أسهم عادية.

Peter FungCardio Diagnostics Holdings, Inc. (CDIO)董事,报告了一项与股票期权相关的非衍生变动,日期为09/30/2025。申报显示有1,559份股票期权被获取,执行价格为$4.01,可立即行使并于09/30/2035到期。交易后,Fung先生直接持有4,002股普通股。

Positive
  • None.
Negative
  • None.

Peter Fung, un direttore di Cardio Diagnostics Holdings, Inc. (CDIO), ha riportato una variazione non derivativa legata a stock options datata 09/30/2025. La filing mostra che 1,559 stock options sono state acquisite con un prezzo di esercizio di $4.01, esercitabili immediatamente e con scadenza il 09/30/2035. Dopo la transazione, il signor Fung deteneva direttamente 4,002 azioni ordinarie.

Peter Fung, un director de Cardio Diagnostics Holdings, Inc. (CDIO), informó un cambio no derivado vinculado a opciones sobre acciones con fecha 09/30/2025. El trámite muestra que se adquirieron 1,559 opciones sobre acciones con un precio de ejercicio de $4.01, exercitables de inmediato y con vencimiento el 09/30/2035. Después de la transacción, el Sr. Fung poseía directamente 4,002 acciones ordinarias.

Peter Fung, 이사Cardio Diagnostics Holdings, Inc. (CDIO)의 비파생적 변화가 09/30/2025에 주식매수선택권과 관련해 보고되었습니다. 공시에는 1,559 주식 옵션이 $4.01의 행사 가격으로 즉시 행사 가능하며 2035/09/30에 만료됩니다. 거래 후 펑 씨는 직접 보유한 일반 주식 4,002주를 소유하게 되었습니다.

Peter Fung, directeur de Cardio Diagnostics Holdings, Inc. (CDIO), a déclaré une modification non dérivée liée à des options sur actions datée du 09/30/2025. Le dépôt indique que 1 559 options sur actions ont été acquises avec un prix d’exercice de $4.01, exercables immédiatement et arrivant à échéance le 09/30/2035. Après la transaction, M. Fung détenait directement 4 002 actions ordinaires.

Peter Fung, ein Direktor von Cardio Diagnostics Holdings, Inc. (CDIO), meldete eine nicht derivative Veränderung im Zusammenhang mit Aktienoptionen datiert auf 09/30/2025. Die Einreichung zeigt, dass 1.559 Aktienoptionen mit einem Ausübungspreis von $4.01 erworben wurden, sofort ausübbar und am 09/30/2035 fällig. Nach der Transaktion besaß Herr Fung direkt 4.002 Stammaktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Fung Peter K

(Last) (First) (Middle)
C/O CARDIO DIAGNOSTICS HOLDINGS INC.
311 W. SUPERIOR ST. SUITE 444

(Street)
CHICAGO IL 60654

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $4.01 09/30/2025 A 1,559 09/30/2025 09/30/2035 Common Stock 1,559 $4.01 4,002 D
Explanation of Responses:
/s/ Elisa Luqman as attorney-in-fact for Peter Fung 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Cardio Diagnostics Holdings Inc

NASDAQ:CDIO

CDIO Rankings

CDIO Latest News

CDIO Latest SEC Filings

CDIO Stock Data

7.70M
1.64M
7.16%
4.81%
0.98%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CHICAGO